United States News Todas as matérias

Brent crude (ICE:BZ) rose just under 4% to $104.18 per barrel on Thursday as renewed tensions involving the United States and Iran increased concerns about global oil supplies.

SpaceX’s (NASDAQ:SPCX) Starlink said it remains ready to launch satellite internet service in India, but the government said the company must complete security assessments before it can seek spectrum.

Taiwan Semiconductor Manufacturing (NYSE:TSM) reported third-quarter 2026 revenue of NT$1.49 trillion, or about $46.7 billion, representing roughly 51% year-over-year growth and exceeding analyst expectations of NT$1.46 trillion.

Biohaven (NYSE:BHVN) entered an exclusive regional licensing agreement with Ono Pharmaceutical covering its IgG degrader portfolio, with near-term payments of up to $100 million.

XPENG (NYSE:XPEV) completed the first production trial of its G9L SUV at Magna’s Graz, Austria facility, making it the fourth XPENG model to undergo production there.

LEIFRAS (NASDAQ:LFS) reported unaudited first-half fiscal 2026 revenue of JPY5,978.8 million for the six months ended June 30, up 8.9% from a year earlier.

argenx (NASDAQ:ARGX) said its Phase 2 study of FB102 in adults with celiac disease met its primary endpoint, showing a statistically significant improvement versus placebo at day 78 with a p-value of 0.0176.

argenx (NASDAQ:ARGX) will discontinue its Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren's disease after an interim analysis found the trial could not meet its primary endpoint.

CME Group (NASDAQ:CME) reported international average daily volume of 9 million contracts in the third quarter of 2026, up 22% from a year earlier.

Hyperfine (NASDAQ:HYPR) expects preliminary unaudited third-quarter 2026 revenue of approximately $6 million, representing 53% sequential growth from the second quarter.

Buckle (NYSE:BKE) reported net sales of $110.8 million for the five-week fiscal month ended October 3, 2026, representing a 2.2% increase from $108.4 million a year earlier.

Levi Strauss (NYSE:LEVI) reported third-quarter 2026 net revenue of $1.6 billion, up 4% on a reported basis and 5% organically from the prior-year period.

Resources Connection (NASDAQ:RGP) reported first-quarter fiscal 2027 revenue of $98.1 million for the period ended August 29, 2026, down 18.4% from $120.2 million a year earlier.

AppFolio (NASDAQ:APPF) shares fell 6.6% to $189.87 on Wednesday after UBS downgraded the real estate software company to Neutral from Buy, citing a more balanced risk-reward outlook.

SpaceX (NASDAQ:SPCX) is reportedly seeking $40 billion in new debt to buy Nvidia (NASDAQ:NVDA) chips for its data centers, while its shares fell about 2% in early Wednesday trading.

Parabolic (NASDAQ:PARA) expects preliminary third-quarter 2026 revenue of approximately $4.7 million, representing 65% year-over-year growth and 106% sequential growth.

Cosmos Health (NASDAQ:COSM) reported preliminary nine-month revenue of approximately $54.3 million for the period ended September 30, 2026.

Safe Pro Group (NASDAQ) expects third-quarter 2026 revenue to exceed $2.5 million, representing growth of more than 2,300% from $101,422 in the same quarter a year earlier.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) announced positive preclinical results for its Bisphosphocin compounds in animal models of urinary tract and pulmonary infections.

Lucas GC (NASDAQ:LGCL) reported its first-half financial results for the period ended June 30, 2026, generating total revenue of $35.74 million (RMB245.3 million).

Google (NASDAQ:GOOGL) and Unity (NYSE:U) announced a strategic partnership to combine artificial intelligence research with industry-leading engine technology for a new era of gaming.

AbbVie (NYSE:ABBV) received two FDA Breakthrough Therapy Designations for its investigational asset, telisotuzumab adizutecan (Temab-A).

TOYO (NASDAQ:TOYO) completed its Texas solar module capacity expansion to 2 GW, hosting a ribbon-cutting ceremony at its Humble facility.

BD (NYSE:BDX) announced nine-month AGILITY trial results showing its Revello Vascular Covered Stent met the primary endpoint with a 97.2% primary patency rate in iliac artery disease.